Top

Published in:

01-04-2004 | Original Research Article

Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Concentrations in Stable Renal Transplant Patients

Authors: Dr Chantal Le Guellec, Hélène Bourgoin, Matthias Büchler, Yann Le Meur, Yvon Lebranchu, Pierre Marquet, Gilles Paintaud

Published in: Clinical Pharmacokinetics | Issue 4/2004

Abstract

Background: Therapeutic drug monitoring of mycophenolic acid (MPA) may minimise the risk of acute rejection after transplantation. Area under the curve (AUC) rather than trough concentration-based monitoring is recommended and models for AUC estimation are needed.

Objective: To develop a population pharmacokinetic model suitable for Bayesian estimation of individual AUC in stable renal transplant patients. Patients and methods: The population pharmacokinetics of MPA were studied using nonlinear mixed effects modelling (NONMEM) in 60 patients (index group) receiving MPA on a twice-daily basis. Ten blood samples were collected at fixed timepoints from ten patients and four blood samples were collected at sparse timepoints from 50 patients. Bayesian estimation of individual AUC was made on the basis of three blood concentration measurements and covariates. The predictive performances of the Bayesian procedure were evaluated in an independent group of patients (test group) comprising ten subjects in whom ten blood samples were collected at fixed timepoints.

Results: A two-compartment model with zero-order absorption best fitted the data. Covariate analysis showed that bodyweight was positively correlated with oral clearance. However, the weak magnitude of the reduction in variability (from 34.8 to 28.2%) indicates that administration on a per kilogram basis would be of limited value in decreasing interindividual variability in MPA exposure. Bayesian estimation of pharmacokinetic parameters using samples drawn at 20 minutes and 1 and 3 hours enabled estimation of individual AUC with satisfactory accuracy (bias 7.7%, range of prediction errors 0.43–15.1%) and precision (root mean squared error 12.4%) as compared with the reference value obtained using the trapezoidal method.

Results: This paper reports for the first time population pharmacokinetic data for MPA in stable renal transplant patients, and shows that Bayesian estimation can allow accurate prediction of AUC with only three samples. This method provides a tool for therapeutic drug monitoring of MPA or for concentration-effect studies. Its application to MPA monitoring in the early period post-transplantation needs to be evaluated.

The use of trade names is for product identification purposes only and does not imply endorsement.

Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34(6): 429–55PubMedCrossRef

Cantin B, Giannetti N, Parekh H, et al. Mycophenolic acid concentrations in long-term heart transplant patients: relationship with calcineurin antagonists and acute rejection. Clin Transplant 2002; 16(3): 196–201PubMedCrossRef

DeNofrio D, Loh E, Kao A, et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant 2000; 19(11): 1071–6PubMedCrossRef

Dubrey SW, Holt DW, Banner N. Measurement of mycophenolate mofetil plasma levels after heart transplantation and a potential side effect of high levels. Ther Drug Monit 1999; 21(3): 325–6PubMedCrossRef

Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998; 64(6): 672–83PubMedCrossRef

Hubner GI, Eismann R, Sziegoleit W. Relationship between mycophenolate mofetil side effects and mycophenolic acid plasma trough levels in renal transplant patients. Arzneimittel Forschung 2000; 50(10): 936–40PubMed

Pillans PI, Rigby RJ, Kubler P, et al. A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients. Clin Biochem 2001; 34(1): 77–81PubMedCrossRef

Sanquer S, Breil M, Baron C, et al. Trough blood concentrations in long-term treatment with mycophenolate mofetil [letter]. Lancet 1998; 351(9115): 1557PubMedCrossRef

Shaw LM, Nowak I. Mycophenolic acid: measurement and relationship to pharmacologic effects. Ther Drug Monit 1995; 17(6): 685–9PubMedCrossRef

10.

Smak Gregoor PJ, Hesse CJ, van Gelder T, et al. Relation of mycophenolic acid trough levels and adverse events in kidney allograft recipients. Transplant Proc 1998; 30(4): 1192–3PubMedCrossRef

11.

Takahashi K, Ochiai T, Uchida K, et al. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee: Japan. Transplant Proc 1995; 27(1): 1421–4PubMed

12.

Oellerich M, Shipkova M, Schutz E, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 2000; 22(1): 20–6PubMedCrossRef

13.

Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002; 13(3): 759–68PubMed

14.

Nicholls AJ. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Clin Biochem 1998; 31(5): 329–33PubMedCrossRef

15.

van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68(2): 261–6PubMedCrossRef

16.

Mourad M, Malaise J, Chaib Eddour D, et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem 2001; 47(7): 1241–8PubMed

17.

Weber LT, Shipkova M, Armstrong VW, et al. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem 2002; 48(3): 517–25PubMed

18.

Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001; 23(4): 305–15PubMedCrossRef

19.

Cattaneo D, Gaspari F, Ferrari S, et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 2001; 15(6): 402–9PubMedCrossRef

20.

Holt DW. Monitoring mycophenolic acid. Ann Clin Biochem 2002; 39 (Pt 3): 173–83PubMedCrossRef

21.

Wong SH. Therapeutic drug monitoring for immunosuppressants. Clin Chim Acta 2001; 313(1–2): 241–53PubMedCrossRef

22.

Mourad M, Wallemacq P, Konig J, et al. Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary? Clin Pharmacokinet 2002; 41(5): 319–27PubMedCrossRef

23.

Stephan A, Masri MA, Barbari A, et al. Therapeutic drug level monitoring for mycophenolate mofetil: is it justified? Transplant Proc 2001; 33(5): 2778–9PubMedCrossRef

24.

Dumont RJ, Ensom MH. Methods for clinical monitoring of cyclosporin in transplant patients. Clin Pharmacokinet 2000; 38(5): 427–47PubMedCrossRef

25.

Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit 2000; 22(2): 169–73PubMedCrossRef

26.

Le Guellec C, Buchler M, Giraudeau B, et al. Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. Eur J Clin Pharmacol 2002; 57(11): 805–11PubMedCrossRef

27.

Schutz E, Armstrong VW, Shipkova M, et al. Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients: German Study Group on MMF Therapy in Pediatrie Renal Transplant Recipients. Transplant Proc 1998; 30(4): 1182–4PubMedCrossRef

28.

Weber LT, Schutz E, Lamersdorf T, et al. Therapeutic drug monitoring of total and free mycophenolic acid (MPA) and limited sampling strategy for determination of MPA-AUC in paediatric renal transplant recipients: The German Study Group on Mycophenolate Mofetil (MMF) Therapy. Nephrol Dial Transplant 1999; 14 Suppl. 4: 34–5PubMedCrossRef

29.

Willis C, Taylor PJ, Salm P, et al. Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients. Ther Drug Monit 2000; 22(5): 549–54PubMedCrossRef

30.

Yeung S, Tong KL, Tsang WK, et al. Determination of mycophenolate area under the curve by limited sampling strategy. Transplant Proc 2001; 33(1–2): 1052–3PubMedCrossRef

31.

Tanigawara Y, Yano I, Kawakatsu K, et al. Predictive performance of the Bayesian analysis: effects of blood sampling time, population parameters, and pharmacostatistical model. J Pharmacokinet Biopharm 1994; 22(1): 59–71PubMed

32.

Aarons L. Software for population pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1999; 36(4): 255–64PubMedCrossRef

33.

Proost JH. Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting. Int J Clin Pharmacol Ther 1995; 33(10): 531–6PubMed

34.

Vozeh S, Steimer JL, Rowland M, et al. The use of population pharmacokinetics in drug development. Clin Pharmacokinet 1996; 30(2): 81–93PubMedCrossRef

35.

Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9(4): 503–12PubMed

36.

Weber LT, Lamersdorf T, Shipkova M, et al. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients: German Study Group on Mycophenolate Mofetil Therapy in Pediatrie Renal Transplant Recipients. Ther Drug Monit 1999; 21(5): 498–506PubMedCrossRef

37.

Pawinski T, Hale M, Korecka M, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002; 48(9): 1497–504PubMed

38.

Buffington DE, Lampasona V, Chandler MH. Computers in pharmacokinetics: choosing software for clinical decision making. Clin Pharmacokinet 1993; 25(3): 205–16PubMedCrossRef

39.

Charpiat B, Falconi I, Breant V, et al. A population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting. Ther Drug Monit 1998; 20(2): 158–64PubMedCrossRef

40.

Ducharme MP, Verret L, Brouillette D, et al. Ability of a firstpass pharmacokinetic model to characterize cyclosporine blood concentrations after administrations of Sandimmune or Neoral formulations. Ther Drug Monit 1998; 20(2): 165–71PubMedCrossRef

41.

Ruggeri A, Martinelli M. A program for the optimization of cyclosporine therapy using population kinetics modeling. Comput Methods Programs Biomed 2000; 61(1): 61–9PubMedCrossRef

42.

Debord J, Risco E, Harel M, et al. Application of a gamma model of absorption to oral cyclosporin. Clin Pharmacokinet 2001; 40(5): 375–82PubMedCrossRef

43.

Leger F, Debord J, Le Meur Y, et al. Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants. Clin Pharmacokinet 2002; 41(1): 71–80PubMedCrossRef

44.

Meier-Kriesche HU, Shaw LM, Korecka M, et al. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther Drug Monit 2000; 22(1): 27–30PubMedCrossRef

45.

Shaw LM, Korecka M, Aradhye S, et al. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol 2000; 40(6): 624–33PubMedCrossRef

46.

Vogl M, Weigel G, Seebacher G, et al. Evaluation of the EMIT mycophenolic acid assay from Dade Behring. Ther Drug Monit 1999; 21(6): 638–43PubMedCrossRef

47.

Funaki T. Enterohepatic circulation model for population pharmacokinetic analysis. J Pharm Pharmacol 1999; 51(10): 1143–8PubMedCrossRef

48.

Brown NW, Aw MM, Mieli-Vergani G, et al. Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. Ther Drug Monit 2002; 24(5): 598–606PubMedCrossRef

49.

Schutz E, Shipkova M, Wieland E, et al. Evaluation of an immunoassay for mycophenolic acid. Ther Drug Monit 2000; 22(1): 141–2PubMedCrossRef

50.

Beal JL, Jones CE, Taylor PJ, et al. Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay. Ther Drug Monit 1998; 20(6): 685–90PubMedCrossRef

Title: Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Concentrations in Stable Renal Transplant Patients
Authors: Dr Chantal Le Guellec
Hélène Bourgoin
Matthias Büchler
Yann Le Meur
Yvon Lebranchu
Pierre Marquet
Gilles Paintaud
Publication date: 01-04-2004
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 4/2004
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.2165/00003088-200443040-00004

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Concentrations in Stable Renal Transplant Patients

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2004

Comparative Pharmacokinetics and Pharmacodynamics of Short-Acting Hypnosedatives

Clinical Pharmacokinetics of Quinupristin/Dalfopristin

Influence of CYP2C9 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy Volunteers

Pharmacokinetic Considerations in Development of a Bioartificial Liver